臨床進度

本網站提及的藥物正在臨床研究中,僅供參考,不用於診斷、治療建議或廣告。

階段2
階段3
Indication
Orphan Drug
MoA
Clinical Trials
2016
2017
2018
2019
2020
2021
2022

Covid-19

view more

Anti-viral

Anti-inflammation

Anti-fibrosis

NSCLC : mono combo,1st line

view more

Ras

inhibitor

Pancreatic cancer

view more
美國 EU

Ras

inhibitor

Acute myeloid leukemia

view more
美國

Ras

inhibitor

Hepatocellular carcinoma

view more
美國

Ras

inhibitor

Atopic dermatitis (AD)

view more

NF-kB

inhibitor

Hypercholesterolemia and Hyperlipidemia

view more

AMPK

Activator

Alzheimer's disease

view more

Nrf2

Activator

Hepatitis B virus

view more

Nrf2

Activator

Indication

Covid-19

Orphan Drug

MoA

Anti-viral

Anti-inflammation

Anti-fibrosis

2020Q2
2022Q2
view more

Indication

NSCLC : mono combo,1st line

Orphan Drug

MoA

Ras

inhibitor

2016
2019
2021Q2
2022Q4
2021Q2
2022Q4
view more

Indication

Pancreatic cancer

Orphan Drug

美國 EU

MoA

Ras

inhibitor

2017Q4
2022Q2
view more

Indication

Acute myeloid leukemia

Orphan Drug

美國

MoA

Ras

inhibitor

2019Q2
2022Q2
view more

Indication

Hepatocellular carcinoma

Orphan Drug

美國

MoA

Ras

inhibitor

view more

Indication

Atopic dermatitis (AD)

Orphan Drug

MoA

NF-kB

inhibitor

2021Q2
2022Q2
view more

Indication

Hypercholesterolemia and Hyperlipidemia

Orphan Drug

MoA

AMPK

Activator

2016Q2
2018Q2
view more

Indication

Alzheimer's disease

Orphan Drug

MoA

Nrf2

Activator

2021Q1
2022Q4
view more

Indication

Hepatitis B virus

Orphan Drug

MoA

Nrf2

Activator

2018
2022Q1
view more